Published in Gastroenterology on November 28, 2007
Hepatitis B: the virus and disease. Hepatology (2009) 2.48
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J (2009) 1.23
Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology (2014) 1.19
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol (2010) 1.15
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat (2012) 1.09
Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem (2013) 1.03
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J (2011) 1.00
Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci (2011) 0.98
Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. Gut Liver (2015) 0.93
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93
Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology (2009) 0.92
Monitoring during and after antiviral therapy for hepatitis B. Hepatology (2009) 0.91
Differences in metabolites of different tongue coatings in patients with chronic hepatitis B. Evid Based Complement Alternat Med (2013) 0.90
Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol (2009) 0.89
Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification. J Clin Microbiol (2011) 0.89
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol (2014) 0.89
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res (2010) 0.86
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol (2015) 0.84
Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol (2009) 0.83
Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses. Open Virol J (2012) 0.82
Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One (2013) 0.82
Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol (2008) 0.81
Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv (2014) 0.81
Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res (2016) 0.80
Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol (2014) 0.79
HBV genotype B/C and response to lamivudine therapy: a systematic review. Biomed Res Int (2013) 0.79
Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol (2013) 0.79
A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. BMC Infect Dis (2014) 0.79
Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. Virol J (2009) 0.78
Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. Hepatol Int (2009) 0.78
An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients. Virol J (2011) 0.77
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol (2014) 0.77
Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. World J Gastroenterol (2008) 0.76
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 0.76
Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Chin Med J (Engl) (2015) 0.75
Tenofovir rescue therapy in pregnant females with chronic hepatitis B. World J Gastroenterol (2015) 0.75
How to compare antivirals in the treatment of chronic hepatitis B? Ann Clin Microbiol Antimicrob (2009) 0.75
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis (2016) 0.75
Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.75
A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepat Mon (2016) 0.75
Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy. Ther Clin Risk Manag (2015) 0.75
[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. Wien Klin Wochenschr (2010) 0.75
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol (2002) 4.22
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology (2003) 3.30
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med (2007) 2.52
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 2.51
Genetic variability in hepatitis B viruses. J Gen Virol (2002) 2.45
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat (2002) 2.26
Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis (2006) 2.23
An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang (2001) 2.15
Molecular diagnosis of viral hepatitis. Gastroenterology (2002) 2.10
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology (2006) 2.05
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat (2003) 1.97
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
HBV drug resistance: mechanisms, detection and interpretation. J Hepatol (2006) 1.71
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol (2000) 1.59
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol (2005) 1.57
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology (2000) 1.56
When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med (2007) 1.48
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45
Dynamics of hepatitis B virus resistance to lamivudine. J Virol (2006) 1.38
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol (2006) 1.35
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol (2004) 1.32
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology (2006) 1.29
Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology (2004) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol (2006) 1.27
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol (2006) 1.24
Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics. J Hepatol (2003) 1.23
Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res (2004) 1.22
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol (2006) 1.17
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol (2006) 1.16
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology (1999) 1.15
Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol (2004) 1.15
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology (2006) 1.10
Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther (2005) 1.10
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat (2000) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Evaluation of the COBAS TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA. J Clin Microbiol (2005) 1.04
Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther (1999) 1.04
The concept of hepatitis B virus mutant escape. J Clin Virol (2005) 1.03
A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology (2004) 1.02
Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. J Virol Methods (2006) 1.00
Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol (2006) 0.98
Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol (2005) 0.90
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology (2000) 0.90
Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother (2005) 0.89
A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol (2003) 0.87
Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. J Clin Virol (2005) 0.86
Comparison of the COBAS TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum. J Med Virol (2005) 0.86
Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood (2005) 0.86
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol (2006) 0.86
Assessment of treatment efficacy in HBV infection and disease. J Hepatol (2005) 0.83
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother (2003) 0.77
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Differentiation of the major Listeria monocytogenes serovars by multiplex PCR. J Clin Microbiol (2004) 4.32
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Wound healing recapitulates morphogenesis in Drosophila embryos. Nat Cell Biol (2002) 4.04
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology (2009) 3.16
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
The role of social scientists in synthetic biology. Science & Society Series on Convergence Research. EMBO Rep (2009) 2.57
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54
New insight in the pathobiology of hepatitis B virus infection. Gut (2012) 2.54
Wound repair at a glance. J Cell Sci (2009) 2.53
Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol (2006) 2.48
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration. J Cell Biol (2005) 2.38
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
New aspects regarding evolution and virulence of Listeria monocytogenes revealed by comparative genomics and DNA arrays. Infect Immun (2004) 2.31